Treatment Selection in Ulcerative Colitis: Optimizing Outcomes through Patient-Centered Decision Making
Podcast 3: New and Emerging Therapies for UC

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Which of the following FDA-approved ulcerative colitis (UC) therapies selectively binds to the p19 subunit of interleukin-23?
A 68-year-old man with type 2 diabetes, hypertension, and moderate to severe congestive heart failure was recently diagnosed with moderate ulcerative colitis (UC). He reports several years of abdominal pain, bleeding, diarrhea and bowel movement urgency. His recent UC flare responded to a course of corticosteroids and he is now being counseled on therapy options. Which of the following would be appropriate for this patient?
Powered by QuestionPro